Canada · Delayed Price · Currency is CAD Curaleaf Holdings Statistics
Total Valuation
TSX:CURA has a market cap or net worth of CAD 3.52 billion. The enterprise value is 4.97 billion.
| Market Cap | 3.52B |
| Enterprise Value | 4.97B |
Important Dates
The next confirmed earnings date is Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSX:CURA has 264.81 million shares outstanding. The number of shares has increased by 3.46% in one year.
| Current Share Class | 233.48M |
| Shares Outstanding | 264.81M |
| Shares Change (YoY) | +3.46% |
| Shares Change (QoQ) | +2.58% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 8.27% |
| Float | 225.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.89 |
| PB Ratio | 2.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 32.91 |
| P/OCF Ratio | 17.61 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.02, with an EV/FCF ratio of 46.44.
| EV / Earnings | n/a |
| EV / Sales | 2.66 |
| EV / EBITDA | 13.02 |
| EV / EBIT | 236.42 |
| EV / FCF | 46.44 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 1.29.
| Current Ratio | 1.52 |
| Quick Ratio | 0.55 |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 4.15 |
| Debt / FCF | 14.78 |
| Interest Coverage | 0.14 |
Financial Efficiency
Return on equity (ROE) is -2.35% and return on invested capital (ROIC) is 0.79%.
| Return on Equity (ROE) | -2.35% |
| Return on Assets (ROA) | 0.32% |
| Return on Invested Capital (ROIC) | 0.79% |
| Return on Capital Employed (ROCE) | 0.59% |
| Weighted Average Cost of Capital (WACC) | 11.26% |
| Revenue Per Employee | 336,297 |
| Profits Per Employee | -13,303 |
| Employee Count | 5,554 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.83 |
Taxes
| Income Tax | -112.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.06% in the last 52 weeks. The beta is 1.60, so TSX:CURA's price volatility has been higher than the market average.
| Beta (5Y) | 1.60 |
| 52-Week Price Change | -2.06% |
| 50-Day Moving Average | 13.83 |
| 200-Day Moving Average | 12.36 |
| Relative Strength Index (RSI) | 39.72 |
| Average Volume (20 Days) | 633,201 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TSX:CURA had revenue of CAD 1.87 billion and -73.89 million in losses. Loss per share was -0.29.
| Revenue | 1.87B |
| Gross Profit | 922.46M |
| Operating Income | 21.04M |
| Pretax Income | -142.69M |
| Net Income | -73.89M |
| EBITDA | 298.07M |
| EBIT | 21.04M |
| Loss Per Share | -0.29 |
Balance Sheet
The company has 134.32 million in cash and 1.58 billion in debt, with a net cash position of -1.45 billion or -5.47 per share.
| Cash & Cash Equivalents | 134.32M |
| Total Debt | 1.58B |
| Net Cash | -1.45B |
| Net Cash Per Share | -5.47 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 4.65 |
| Working Capital | 228.19M |
Cash Flow
In the last 12 months, operating cash flow was 200.20 million and capital expenditures -93.10 million, giving a free cash flow of 107.10 million.
| Operating Cash Flow | 200.20M |
| Capital Expenditures | -93.10M |
| Depreciation & Amortization | 278.27M |
| Net Borrowing | 40.98M |
| Free Cash Flow | 107.10M |
| FCF Per Share | 0.40 |
Margins
Gross margin is 49.39%, with operating and profit margins of 1.13% and -2.63%.
| Gross Margin | 49.39% |
| Operating Margin | 1.13% |
| Pretax Margin | -7.64% |
| Profit Margin | -2.63% |
| EBITDA Margin | 15.96% |
| EBIT Margin | 1.13% |
| FCF Margin | 5.71% |
Dividends & Yields
TSX:CURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.46% |
| Shareholder Yield | -3.46% |
| Earnings Yield | -2.10% |
| FCF Yield | 3.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for TSX:CURA is 18.93, which is 42.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 18.93 |
| Price Target Difference | 42.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 8.71% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 5, 2026. It was a reverse split with a ratio of 0.3333333.
| Last Split Date | Jun 5, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.3333333 |
Scores
TSX:CURA has an Altman Z-Score of 0.44 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.44 |
| Piotroski F-Score | 5 |